Back to results
US 2024/0123074 A1Published application
Minimally toxic prodrugs
AssigneeCobiores NV
InventorAndré TROUET
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.
Claims20
1-30. (canceled)
A prodrug having the general structure:
- [Cx-OP]y-D,
- wherein C is a capping group;
- OP is a tetrapeptide with the sequence ALGP (SEQ ID NO:
- 1), TSGP (SEQ ID NO:
- 4), or KLGP (SEQ ID NO:
- 6);
- D is a drug;
- x is an integer of at least 1;
- x is 1 when y=1;
- y is an integer being at least 1, if y is greater than 1, then at least 1 OP is carrying a capping group;
- and
- wherein the linkage between C and OP is direct;
- wherein the linkage between OP and D is direct or via a linker or spacing group;
- wherein, if y is greater than 1, the multiple OP moieties are individually linked to each other directly or via a linker or spacing group and/or are individually linked to D directly or via a linker or spacing group;
- or a pharmaceutically acceptable salt of the prodrug.
12 more elements
Dependencies are inferred from the claim text.